NSE:ARISTO-SM

Aristo Bio-tech An · NSE · Basic Materials · INR · FY for 2026

Figures on this page computed 2026-11-08 12:47 UTC

Last close

n/aINR

Market data

9.4xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
INR
- computed
- Computed from the filing for 2026
26.8%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
INR
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
2.0%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
INR
- Computed from the filing for 2026
- Computed from the filing for 2026
1.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
INR
- Computed from the filing for 2026
- Computed from the filing for 2026
0.80Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
INR
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
INR
- computed

Safety is the furthest below its sector's middle: 0.35 against 0.56 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.55x

2.29x

3.20x

1.55x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2026

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2026

Sales1.55x
Its own average over 8 years, 2.35B.
Profit2.29x
Its own average over 8 years, 31.3M.
Free cash flow3.20x
Its own average over 8 years, 17.1M.
Debt1.55x
Its own average over 8 years, 228.1M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 3.20 times.

Sales is 1.55 times its own 8-year average; Profit is 2.29 times its own 8-year average; Free cash flow is 3.20 times its own 8-year average; Debt is 1.55 times its own 8-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2026

Sales against its own 8-year average1.55
Source
computed
Statement
income
Fiscal year
2026
Reported in
INR
Profit against its own 8-year average2.29
Source
computed
Statement
income
Fiscal year
2026
Reported in
INR
Free cash flow against its own 8-year average3.20
Source
computed
Statement
income
Fiscal year
2026
Reported in
INR
Debt against its own 8-year average1.55
Source
computed
Statement
income
Fiscal year
2026
Reported in
INR
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
INR